Literature DB >> 31735728

High Plasma Levels of Legumain in Patients with Complex Coronary Lesions.

Tomohiko C Umei1, Yoshimi Kishimoto2, Masayuki Aoyama1, Emi Saita2, Hanako Niki1, Yukinori Ikegami1, Reiko Ohmori3, Kazuo Kondo2,4, Yukihiko Momiyama1.   

Abstract

AIM: The degradation of the vascular extracellular matrix is important for atherosclerosis. The cysteine protease legumain was shown to be upregulated in atherosclerotic plaques, especially unstable plaques. However, no study has reported blood legumain levels in patients with coronary artery disease (CAD).
METHODS: We investigated plasma legumain and C-reactive protein (CRP) levels in 372 patients undergoing elective coronary angiography.
RESULTS: CAD was found in 225 patients. Compared with patients without CAD, those with CAD had higher CRP levels (median 0.60 [0.32, 1.53] vs. 0.46 [0.22, 0.89] mg/L, P<0.001), but no difference was found in legumain levels between patients with and without CAD (median 5.08 [3.87, 6.82] vs. 4.99 [3.84, 6.88] ng/mL). A stepwise increase in CRP was found depending on the number of >50% stenotic vessels: 0.55 mg/L in 1-vessel, 0.71 mg/L in 2-vessel, and 0.86 mg/L in 3-vessel diseases (P<0.001). However, legumain did not differ among 1-, 2-, and 3-vessel diseases (5.20, 4.93, and 5.01 ng/mL, respectively). Of 225 patients with CAD, 40 (18%) had complex lesions. No difference was found in CRP levels between patients with CAD with and without complex lesions (0.60 [0.34, 1.53] vs. 0.60 [0.32, 1.51] mg/L). Notably, legumain levels were higher in patients with CAD with complex lesions than without such lesions (6.05 [4.64, 8.64] vs. 4.93 [3.76, 6.52] ng/mL, P<0.01). In multivariate analysis, legumain levels were not a factor for CAD, but were a factor for complex lesions. The odds ratio for complex lesions was 2.45 (95% CI=1.26-4.79) for legumain >5.5 ng/mL.
CONCLUSION: Plasma legumain levels were associated with the presence of complex coronary lesions.

Entities:  

Keywords:  Coronary artery disease; Legumain; Plaque instability

Mesh:

Substances:

Year:  2019        PMID: 31735728      PMCID: PMC7406406          DOI: 10.5551/jat.52027

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  33 in total

Review 1.  Atherosclerosis. the road ahead.

Authors:  C K Glass; J L Witztum
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

2.  Prognostic implications of lesion irregularity on coronary angiography.

Authors:  J A Ambrose
Journal:  J Am Coll Cardiol       Date:  1991-09       Impact factor: 24.094

3.  Pleiotropic effects of atorvastatin on monocytes in atherosclerotic patients.

Authors:  Zhi-hao Wang; Xiao-lin Liu; Ming Zhong; Li-ping Zhang; Yuan-yuan Shang; Xiao-yan Hu; Li Li; Yun Zhang; Jing-ti Deng; Wei Zhang
Journal:  J Clin Pharmacol       Date:  2009-10-06       Impact factor: 3.126

Review 4.  Lysosomal cysteine proteases in atherosclerosis.

Authors:  Jian Liu; Galina K Sukhova; Jiu-Song Sun; Wei-Hua Xu; Peter Libby; Guo-Ping Shi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-06-03       Impact factor: 8.311

5.  Association between complex coronary artery stenosis and unstable angina and the extent of plaque inflammation.

Authors:  Martijn Meuwissen; Allard C van der Wal; Karel T Koch; Chris M van der Loos; Steven A J Chamuleau; Peter Teeling; Robbert J de Winter; Jan G P Tijssen; Anton E Becker; Jan J Piek
Journal:  Am J Med       Date:  2003-05       Impact factor: 4.965

6.  High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama study.

Authors:  Hisatomi Arima; Michiaki Kubo; Koji Yonemoto; Yasufumi Doi; Toshiharu Ninomiya; Yumihiro Tanizaki; Jun Hata; Kiyoshi Matsumura; Mitsuo Iida; Yutaka Kiyohara
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-04-10       Impact factor: 8.311

7.  Legumain and cathepsin-L expression in human unstable carotid plaque.

Authors:  K L Mattock; P J Gough; J Humphries; K Burnand; L Patel; K E Suckling; F Cuello; C Watts; M Gautel; M Avkiran; A Smith
Journal:  Atherosclerosis       Date:  2009-08-09       Impact factor: 5.162

8.  Legumain suppresses OxLDL-induced macrophage apoptosis through enhancement of the autophagy pathway.

Authors:  Wenhua Sun; Yingying Lin; Liling Chen; Rong Ma; Jiayu Cao; Jing Yao; Kaihong Chen; Jieqing Wan
Journal:  Gene       Date:  2018-02-04       Impact factor: 3.688

9.  Local carotid atherosclerotic plaque proteins for the identification of circulating biomarkers in coronary patients.

Authors:  Eric Malaud; Delphine Merle; Dominique Piquer; Laurence Molina; Nicolas Salvetat; Laetitia Rubrecht; Emilie Dupaty; Pascale Galea; Sandra Cobo; Aurélie Blanc; Max Saussine; Charles Marty-Ané; Bernard Albat; Olivier Meilhac; Francois Rieunier; Agnes Pouzet; Franck Molina; Daniel Laune; Jeannette Fareh
Journal:  Atherosclerosis       Date:  2014-01-18       Impact factor: 5.162

10.  Morphology of left anterior descending coronary territory lesions as a predictor of anterior myocardial infarction: a CASS Registry Study.

Authors:  S Ellis; E L Alderman; K Cain; A Wright; M Bourassa; L Fisher
Journal:  J Am Coll Cardiol       Date:  1989-06       Impact factor: 24.094

View more
  3 in total

1.  Serum Legumain Is Associated with Peripheral Artery Disease in Patients with Type 2 Diabetes.

Authors:  Wen Wei; Shujin Chen; Jianqing Huang; Yan Tong; Jushun Zhang; Xiuping Qiu; Wenrui Zhang; Hangju Chen; Rong Huang; Jin Cai; Mei Tu
Journal:  J Diabetes Res       Date:  2021-12-18       Impact factor: 4.011

2.  Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) Trial.

Authors:  Ida Gregersen; Annika E Michelsen; Ngoc Nguyen Lunde; Axel Åkerblom; Tatevik G Lakic; Mona Skjelland; Karolina Ryeng Skagen; Richard C Becker; Johan Lindbäck; Anders Himmelmann; Rigmor Solberg; Harald T Johansen; Stefan K James; Agneta Siegbahn; Robert F Storey; Frederic Kontny; Pål Aukrust; Thor Ueland; Lars Wallentin; Bente Halvorsen
Journal:  J Am Heart Assoc       Date:  2020-08-15       Impact factor: 5.501

3.  Identification of the Cysteine Protease Legumain as a Potential Chronic Hypoxia-Specific Multiple Myeloma Target Gene.

Authors:  Ada-Sophia Clees; Verena Stolp; Björn Häupl; Dominik C Fuhrmann; Frank Wempe; Marcel Seibert; Sarah Weber; Antje Banning; Ritva Tikkanen; Richard Williams; Bernhard Brüne; Hubert Serve; Frank Schnütgen; Ivana von Metzler; Nina Kurrle
Journal:  Cells       Date:  2022-01-15       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.